Sign up
Pharma Capital

OptiBiotix Health says SlimBiome to be used in Cereal Ingredients' Nutri-Bites range of cereal products

The AIM-listed obesity and cholesterol management company said that the partnership would extend the application of its SlimBiome® technology in breakfast cereals and bakery products
Measuring stomach
The product range will be showcased at the 2018 Natural Products Expo West & Engredea

OptiBiotix Health plc (LON:OPTI) has announced that its SlimBiome weight management technology will be used in US partner Cereal Ingredients' (CII) Nutri-Bites range of cereal products.

The AIM-listed obesity and cholesterol management firm said that the partnership will extend the application of SlimBiome® into products such as breakfast cereals and cookies, cakes as well as a range of healthy snacks, yoghurts, and cereal bars.

READ: OptiBiotix rises as its signs a production and commercialisation agreement

OptiBiotix said the move was a continuation of its focus on the US market following a supply and manufacturing agreement signed with CII in December 2017.

The group added that product range will be showcased at the 2018 Natural Products Expo West & Engredea, the world’s largest trade show for organic, natural and healthy products.

WATCH: Optibiotix to launch SlimBiome in Nutri-Bites with US partner

OptiBiotix's sales and marketing director, Christina Wood, said: “By combining OptiBiotix's award-winning SlimBiome® technology with CII's market-leading ingredients, manufacturing capacity and product development, we have created a delicious functional solution which can help customers manage their weight by reducing snacking and food intake without food cravings.

"We are delighted to share this innovative science-based approach to weight management with food and ingredient buyers from around the world at the Natural Products Expo West & Engredea show."

View full OPTI profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.